ArticleAmerican family physician2015
Pharmacogenetics: Using Genetic Information to Guide Drug Therapy.
Article in American family physician, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 26 citations in OpenAlex.
- Drug-gene and drug-drug interactions associated with tramadol and codeine therapy in the INGENIOUS trial.Pharmacogenomics · 2019Trial
- CYP2D6 pharmacogenetic and oxycodone pharmacokinetic association study in pediatric surgical patients.Pharmacogenomics · 2017Trial
- A de novo algorithm for allele reconstruction from Oxford nanopore amplicon reads, with application to CYP2D6.Bioinformatics (Oxford, England) · 2026Article
- Knowledge, attitudes, and perceptions of pharmacogenetic testing in swiss community pharmacies: a mixed-methods study among physicians, pharmacists, and the general public.Frontiers in pharmacology · 2026Article
- Evaluation of an electronic health record Drug Interaction Customization Editor (DICE).American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists · 2024Article
- Digital Technologies: Advancing Individualized Treatments through Gene and Cell Therapies, Pharmacogenetics, and Disease Detection and Diagnostics.Biomedicines · 2022Article
- Role of the gut microbiome in cardiovascular drug response: The potential for clinical application.Pharmacotherapy · 2022Review
- Pharmacogenomics and Cardiovascular Disease: Where are We and Where do We go from Here?Arquivos brasileiros de cardiologia · 2020Article
- The implementation of pharmacogenomics into UK general practice: a qualitative study exploring barriers, challenges and opportunities.Journal of community genetics · 2020Article
- Clinical Relevance of CYP2D6 Polymorphisms in Patients of an Austrian Medical Practice: A Family Practice-Based Observational Study.Drugs - real world outcomes · 2020Article
- Laying Anchor: Inserting Precision Health into a Public Health Genetics Policy Course.Healthcare (Basel, Switzerland) · 2018Article
- Making genomic medicine evidence-based and patient-centered: a structured review and landscape analysis of comparative effectiveness research.Genetics in medicine : official journal of the American College of Medical Genetics · 2017Review
Corrections and comments
- Commented on by
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Clinical pharmacogenetics, the use of genetic data to guide drug therapy decisions, is beginning to be used for medications commonly prescribed by family physicians. However, clinicians are largely unfamiliar with principles supporting clinical use of this type of data. For example, genetic variability in the cytochrome P450 2D6 drug metabolizing enzyme can alter the clinical effects of some opioid analgesics (e.g., codeine, tramadol), whereas variability in the CYP2C19 enzyme affects the antiplatelet agent clopidogrel. If testing is performed, patients who are ultrarapid or poor metabolizers of CYP2D6 should avoid codeine use (and possibly tramadol, hydrocodone, and oxycodone) because of the potential for increased toxicity or lack of effectiveness. Patients undergoing percutaneous coronary intervention for acute coronary syndromes who are known to be poor metabolizers of CYP2C19 should consider alternate antiplatelet therapy (e.g., ticagrelor, prasugrel). Some guidelines are available that address appropriate drug therapy changes, and others are in development. Additionally, a number of clinical resources are emerging to support family physicians in the use of pharmacogenetics. When used appropriately, pharmacogenetic testing can be a practical tool to optimize drug therapy and avoid medication adverse effects.
Indexed as
Identifiers
26447442PMC4729205W2403324463What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.